Mealey's (October 7, 2015, 11:23 AM EDT) -- PHILADELPHIA — Efforts by a direct purchaser class of the brand-name drug Provigil, covered by U.S. reissue patent No. 37,516, to preclude experts for five pharmaceutical companies from opining, generally, that reverse-payment agreements that settled related infringement litigation were procompetitive were thwarted Oct. 5 by a Pennsylvania federal judge (King Drug Company of Florence Inc., et al. v. Cephalon Inc., et al., No. 06-1797, E.D. Pa.; 2015 U.S. Dist. LEXIS 135264)....